Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden
· Delayed Price · Currency is SEK 9.66
-0.59 (-5.76%)
Apr 29, 2026, 3:56 PM CET
Xbrane Biopharma AB Revenue
In the year 2025, Xbrane Biopharma AB had annual revenue of 152.35M SEK with 2.87% growth. Xbrane Biopharma AB had revenue of 9.09M in the quarter ending December 31, 2025.
Revenue
152.35M
Revenue Growth
+2.87%
P/S Ratio
1.39
Revenue / Employee
5.25M
Employees
26
Market Cap
211.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 152.35M | 4.26M | 2.87% |
| Dec 31, 2024 | 148.10M | -90.63M | -37.96% |
| Dec 31, 2023 | 238.73M | 181.11M | 314.33% |
| Dec 31, 2022 | 57.62M | 46.91M | 438.03% |
| Dec 31, 2021 | 10.71M | - | - |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xintela AB | 2.28M |
| Diamyd Medical AB | 362.00K |
| Elicera Therapeutics AB | 10.64M |
| Alligator Bioscience AB | 839.00K |
| Mendus AB | -1.44M |
| Bio-Works Technologies AB | 63.11M |
| NextCell Pharma AB | 9.83M |